Qube Blog

Behind every new treatment there is much more than a scientific discovery.
Identifying a promising molecule, a new therapeutic target or a technology capable of acting on a disease may be the starting point. But between that discovery and its possible arrival to patients, there is a complex process.

Artificial intelligence in drug development is steadily expanding its range of applications.
How can we ensure that the results produced by an AI system are reliable enough to support scientific and regulatory decisions?

Stablepharma and SmartBio Analytics have been recognised for their contribution to scientific development, biomedical innovation and improved access to treatments.

Escuela Genetica ATG organises a 1st edition "Monographic course on DNA sequencing: Sanger vs NGS (Next Generation Sequencing)" the 5th and 6th of October. Main goal is to provide with the basic concepts of DNA sequencing by Sanger and NGS methods and their...

QUBE launches its new web page and corporate identity with the compromise to provide the best services to all companies at the Technology Park.

Vivotecnia Research has renovated its instalations at QUBE to extend its offer to preclinical inhalation toxicology by aerosols and smoke. Vivotecnia Research is a contract research laboratory with laboratories and offices at QUBE. Vivotecnia laboratories are...